PAs and NPs of the Florida Keys

Advancing Schizophrenia Treatment: The Latest Evidence on Long-Acting Injectable Therapies

CE Information
0.5 CME credits
Completion Time
30 minutes
Available Until
August 17, 2024
Posted By
Prime CE
Prime CE Prime CE
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.

Overview

Specialties
Psychiatric / Mental Health
Clinical Topics
Schizophrenia

Intended Audience: Psychiatrists, nurse practitioners, physician assistants, nurses, pharmacists, case managers, and psychologists working in psychiatry specialty settings

Optimal treatment of schizophrenia requires lifelong use of antipsychotic agents to manage the hallucinations, delusions, and other positive and negative symptoms of the illness. Long-acting injectable (LAI) therapies have been associated with reduced morbidity and mortality as well as substantial improvements in patient adherence. Join us for an expert-lead on-demand video on the latest clinical evidence on long-acting injectable therapies, how and when LAIs can be incorporated into treatment plans, a review of recent guideline recommendations, and best strategies for overcoming barriers, reducing relapses, and engaging patients with schizophrenia in shared decision-making.

This activity is delivered in partnership with NTOCC.

This activity is part of a series, learners seeking American Psychological Association (APA) credit must complete all activities in this Learning Lab.

Learning Objectives

  • Apply guidelines and evidence on the efficacy, safety, and adherence potential of long-acting injectable antipsychotic therapies to treatment decisions
  • Engage patients and their caregivers in shared decision-making to guide individualized treatment plans that address clinical needs, side effects, long-term goals, and preferences

Speakers

John Kane
John Kane MD

Director, Institute of Behavioral Science, Feinstein Institutes for Medical Research
Professor, Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Jose Rubio
Jose Rubio MD

Assistant Professor of Psychiatry
Donald and Barbara Zucker School of Medicine at Hofstra University / Northwell, Hempstead, NY
Institute of Behavioral Science, Feinstein Institute of Medical Research, Manhasset, NY

CE Information

This activity offers 0.5 CME credits to attendees.

Disclosures

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

  • John M. Kane, M.D (Speaker)
    Advisory Board or Panel  Cerevel, Click Therapeutics, Dainippon Sumitomo, H. Lundbeck, Merck, Newron, Novartis, Otsuka, Teva Pharmaceuticals
    Consultant  Alkermes, Allergan, Boehringer Ingelheim, Cerevel, Dainippon Sumitomo, H. Lundbeck, HLS, HealthRhythms, Indivior, Intracellular Therapies, Janssen Pharmaceutical, Johnson & Johnson, LB Pharmaceuticals, Merck, Minerva, NW Pharma Tech, Neurocrine, Newron, Novartis, Otsuka, Roche, Saladax, Sunovion, Teva Pharmaceuticals
    Grants / Research Support  H. Lundbeck, Janssen Pharmaceutical, Otsuka, Sunovion, Teva Pharmaceuticals
    Stock / Shareholder (self- managed)  LB Pharmaceuticals, MedinCell, NW Pharma Tech, North Shore Therapeutics, Vanguard Research Group
    Other Financial or Material Support (royalties, patents, etc.)  UpToDate
    The relationships reported above are related to the following therapeutic area: Psychiatry
  • Jose M Rubio, MD (Speaker)
    Advisory Board or Panel  Janssen, Karuna, Teva Pharmaceuticals
    Consultant  Medscape
    Grants / Research Support  Alkermes
    Speakers Bureau or other Promotional Education  Teva Pharmaceuticals
    Other Financial or Material Support (royalties, patents, etc.)  UpToDate
    The relationships reported above are related to the following therapeutic area: Psychiatry

The following individuals have no relevant financial relationships with ineligible companies to disclose:

  • M David Rudd, PhD, ABPP (Reviewer)
  • Abimbola Farinde, PhD, PharmD (Planner)
  • Joyce M Knestrick, PhD, CRNP, FAANP (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.


Ready to start this activity?

Login required. You will be redirected to an external website to register for and complete this activity.

Log in and start activity